Breaking News Instant updates and real-time market news.

TZA

Small Cap Bear 3x

$47.07

1.06 (2.30%)

, ADT

ADT Inc.

$6.15

0.06 (0.99%)

08:45
09/30/19
09/30
08:45
09/30/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Direxion Daily Small Cap Bear 3X Shares (TZA) 5.94% +0.90, ADT (ADT) 9.88% +0.82, Sonos (SONO) 1.04% +0.74, Pareteum Corp (TEUM) 28.49% +0.39, ProShares UltraPro Short S&P 500 (SPXU) 2.59% +0.31, Village Farms International (VFF) 19.59% +0.30, Direxion Daily 20 plus Year Treasury Bull 3X Shares (TMF) 4.78% +0.23, MannKind (MNKD) 4.66% +0.21, USA Technologies (USAT) 1.07% +0.20, and Southwestern Energy (SWN) 0.46% +0.18.

TZA

Small Cap Bear 3x

$47.07

1.06 (2.30%)

ADT

ADT Inc.

$6.15

0.06 (0.99%)

SONO

Sonos

$13.49

0.05 (0.37%)

TEUM

Pareteum

$1.32

0.035 (2.72%)

VFF

Village Farms

$8.98

-0.135 (-1.48%)

MNKD

MannKind

$1.26

-0.045 (-3.45%)

USAT

USA Technologies

$4.36

(0.00%)

SWN

Southwestern Energy

$2.04

0.03 (1.49%)

  • 02

    Oct

  • 25

    Oct

  • 12

    Nov

TZA Small Cap Bear 3x
$47.07

1.06 (2.30%)

ADT ADT Inc.
$6.15

0.06 (0.99%)

03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SONO Sonos
$13.49

0.05 (0.37%)

09/04/19
JEFF
09/04/19
NO CHANGE
Target $16
JEFF
Buy
Sonos price target raised to $16 from $12 at Jefferies
Jefferies analyst Brent Thill raised his price target for Sonos to $16 from $12 saying he's "incrementally more positive" given an improved product cycle due to the IKEA partnership, "consistent" quarterly execution, and a "reasonable" valuation. While the analyst questions the recurring nature of the business, he believes that the IKEA partnership will help expand Sonos' addressable market. He sees a "positive short-term trade" but keeps a Hold rating on Sonos given the competitive landscape.
08/19/19
08/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Aramark (ARMK) upgraded to Buy from Neutral at Nomura Instinet and to Buy from Hold at Stifel. 2. Sonos (SONO) upgraded to Strong Buy from Outperform at Raymond James with analyst Adam Tindle saying he sees a "free option" on Sonos' product roadmap over the next few quarters as the company scales beyond its existing markets. 3. Deckers Brands (DECK) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz saying there are now early indications that October/November weather could be favorable, which would suggest potential upside to Deckers' FY20 sales and gross margin guidance, adding that he continues to like what's happening with Hoka as brand momentum remains strong through the first half of the second quarter, with this being another source of potential upside to the year. 4. Aecom (ACM) double upgraded to Overweight from Equal Weight at Barclays with analyst Adam Seiden saying the company has among the lowest exposure to trade in his coverage and also has "an activist put." 5. ON Semiconductor (ON) double upgraded to Strong Buy from Market Perform at Raymond James with analyst Chris Caso citing reset expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
08/19/19
UPGRADE

Strong Buy
Sonos upgraded to Strong Buy as it scales to outside markets at Raymond James
As previously reported, Raymond James upgraded Sonos to Strong Buy from Market Perform and established a $19 price target. Analyst Adam Tindle sees a "free option" on Sonos' product roadmap over the next few quarters as the company scales beyond its existing markets. Tindle is encouraged by early IKEA partnership checks and thinks it could "prime the pump" for future Sonos purchases. The analyst anticipate further product announcements, one potentially at the end of August, that will further scale Sonos "outside the home."
08/19/19
RAJA
08/19/19
UPGRADE
RAJA
Strong Buy
Sonos upgraded to Strong Buy from Outperform at Raymond James
TEUM Pareteum
$1.32

0.035 (2.72%)

07/01/19
LSCM
07/01/19
NO CHANGE
Target $6.5
LSCM
Buy
Pareteum announcement should reinforce confidence, says Lake Street
Lake Street analyst Eric Martinuzzi believes Pareteum's preannouncement this morning should reinforce confidence for "those wondering if current fundamentals would run counter to recent bearish speculation." The company announced its revenue will be above the $26.2M six analyst consensus estimate, Martinuzzi tells investors in a research note. He keeps a Buy rating on the shares with a $6.50 price target.
06/27/19
LSCM
06/27/19
NO CHANGE
Target $6.5
LSCM
Buy
Pareteum fundamentals 'solid' despite stock selloff, says Lake Street
Lake Street analyst Eric Martinuzzi, says that despite the pullback in shares of Pareteum, the company's fundamentals "remain solid." Pareteum is executing well on its Q2 and 2019 plan, says the analyst, who believes investors will be "pleasantly surprised by the rapid growth in connections enabled by the Pareteum Cloud." Martinuzzi sees the current share price as an "unexpected bargain for growth stock investors." He keeps a Buy rating on Pareteum with a price target of $6.50.
08/07/19
LSCM
08/07/19
NO CHANGE
Target $7
LSCM
Buy
Pareteum target raised to $7 on continued execution at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Pareteum to $7 from $6.50 following the company's better than expected Q2 results. The company continues to execute and now serves nearly 1,100 customers in managed services, cloud recurring services, and on-demand APIs, Martinuzzi tells investors in a research note. He keeps a Buy rating on Pareteum shares.
06/28/19
MAXM
06/28/19
NO CHANGE
Target $9
MAXM
Buy
Pareteum short reports create compelling buying opportunity, says Maxim
Maxim analyst Allen Klee said his travels with Pareteum management have reinforced his confidence in his 2019 earnings forecast and that its iPass acquisition appears to be going well. A recent short-seller report, which he notes is the second one in three weeks, uses "cherry-picking and faulty logic to reach inaccurate conclusions," contends Klee, who sees the reports having created a "compelling" opportunity to buy the stock. He keeps a Buy rating and $9 price target on Pareteum shares.
VFF Village Farms
$8.98

-0.135 (-1.48%)

06/13/19
ROTH
06/13/19
INITIATION
Target $25
ROTH
Buy
Village Farms initiated with a Buy at Roth Capital
Roth Capital analyst Scott Fortune started coverage of Village Farms with a Buy rating and $25 price target. The analyst notes that the company is converting its 10.6M sq. ft. tomato greenhouse infrastructure in North America, to new profitable cannabis/hemp cultivation. Established distribution and relationships with the biggest U.S. retailers allow potential new CBD product sales, he contends, adding that Village Farms can easily convert into cannabis cultivation once federally legal in the U.S. and Mexico.
07/22/19
CHLM
07/22/19
INITIATION
Target $30
CHLM
Buy
Village Farms initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Eric Des Lauriers initiated Village Farms with a Buy rating and a price target of $30, saying the company is becoming a "dominant" cannabis cultivator and has a large opportunity in U.S. hemp space. The analyst notes that Village Farms is exceeding cannabis yield and quality expectations and believes the company has a low-cost path to becoming a dominant cultivator, with potential to "far exceed" consensus estimates beginning in 2020.
MNKD MannKind
$1.26

-0.045 (-3.45%)

03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/19
HCWC
05/08/19
NO CHANGE
Target $3
HCWC
Buy
MannKind price target lowered to $3 from $4 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $3 from $4 saying that while Q2 is already shaping up better than Q1, the slower Afrezza ramp drives an estimate reduction. The analyst, however, still believes MannKind's pipeline "is all potential upside" to his model. He keeps a Buy rating on the shares.
05/14/19
BTIG
05/14/19
INITIATION
Target $3
BTIG
Buy
MannKind initiated with a Buy, $3 price target at BTIG
BTIG analyst Robert Hazlett initiated coverage of MannKind with a Buy rating and $3 price target. The stock closed Monday down 2c to $1.23. With the advancements of continuous glucose monitor technologies, tighter glycemic control will become more of a focus, and MannKind's Afrezza "can play a material role," Hazlett tells investors in a research note. The analyst estimates inhaled insulin Afrezza's peak U.S. sales at greater than $350M. Mannkind's recently revamped management is attempting to energize Afrezza through publications of differentiating data, which can improve acceptance among physicians and patients, helping "solid growth continue," according to Hazlett.
05/14/19
05/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with a Buy, $3 price target at BTIG. 2. Ross Stores (ROST) and TJX (TJX) initiated with an Outperform at Baird. 3. Elastic (ESTC) initiated with a Hold at Stifel. 4. CytomX Therapeutics (CTMX) initiated with an Overweight at Cantor Fitzgerald. 5. FIS (FIS) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
USAT USA Technologies
$4.36

(0.00%)

02/11/19
LSCM
02/11/19
DOWNGRADE
LSCM
Hold
USA Technologies downgraded to Hold from Buy at Lake Street
06/06/19
LSCM
06/06/19
NO CHANGE
Target $7
LSCM
Hold
USA Technologies price target raised to $7 from $4.50 at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for USA Technologies to $7 from $4.50 saying the steps the company has taken coupled with Hudson Executive Capital's recent active stake filing have "helped raised the floor on the stock." The analyst, however, keeps a Hold rating on the shares due to the lack of audited financials.
05/24/19
SPHN
05/24/19
NO CHANGE
SPHN
Global Payments, TSYS tie-up would likely be highly accretive, says Stephens
Stephens analyst Brett Huff noted that Bloomberg reports that Global Payments (GPN) and TSYS (TSS) have held talks about a potential merger, joint venture and/or partnerships. While he has previously thought that Global Payments had the luxury of "waiting and seeing" if combining consumer funding account with a merchant POS experience, such as the Fiserv (FISV)-First Data (FDC) and FIS (FIS)-Worldpay (WP) deals will do, would yield enough strategic value, he suspects a sooner deal might be driven by the companies' desire to not just achieve larger scale but also achieve that scale with high-quality assets. Huff said he thinks any deal would likely be highly accretive given overlaps and both companies' track record for realizing cost synergies and he also sees limited antitrust concern. Huff also thinks a Global Payments-TSYS combination would increase the chances that assets such as ACI Worldwide (ACIW), Bottomline Technologies (EPAY), Jack Henry (JKHY), USA Technologies (USAT) and Q2 Holdings (QTWO) would likely be bought.
02/11/19
LSCM
02/11/19
DOWNGRADE
Target $4.5
LSCM
Hold
Lake Street downgrades USA Technologies to Hold on auditor resignation
Lake Street analyst Jaeson Schmidt downgraded USA Technologies to Hold from Buy and cut his price target for the shares to $4.50 from $7.50. Last week's auditor resignation is "another frustrating development to an already frustrating situation and shifts the timeline farther to the right," Schmidt tells investors in a research note. With the delayed financial statements arriving the first quarter after pricing an equity offering at $11 per share, it was already going to be difficult rebuilding credibility with investors, and this news now likely makes this impossible for some investors, the analyst says. He thinks the "near-, and likely medium-term, ceiling has been lowered" and remains concerned how long it will take USA Technologies to rebuild credibility.
SWN Southwestern Energy
$2.04

0.03 (1.49%)

09/19/19
WOLF
09/19/19
UPGRADE
WOLF
Peer Perform
Southwestern Energy upgraded to Peer Perform from Underperform at Wolfe Research
Wolfe Research upgraded Southwestern Energy to Peer Perform from Underperform citing potential to achieve a neutral free-cash-flow goal for YE20.
08/14/19
UBSW
08/14/19
UPGRADE
Target $1.9
UBSW
Neutral
Southwestern Energy upgraded to Neutral from Sell at UBS
UBS analyst Lloyd Byrne upgraded Southwestern Energy to Neutral while also lowering his price target to $1.90 from $3.10. The analyst notes the stock has been under "significant" pressure around NGL and natural gas price expectations' impact on future cash flows. However, the analyst estimates the current net asset value for the stock around $1.90 per share based on the current NGL pricing and existing costs, adding that the company has also made restructuring progress that includes the sale of the Fayetteville and debt reduction.
07/10/19
07/10/19
DOWNGRADE
Target $2

Underperform
Southwestern Energy downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst William Featherston downgraded Southwestern Energy to Underperform from Neutral as he believes it is "structurally challenged" in a low gas and NGL price environment. Even assuming the slightly more "constructive" 2020-23 futures strip, the analyst believes the company is poised to generate material free cash flow deficits over this time period that weighs on both its over-leveraged balance sheet and weak debt-adjusted growth profile. Featherston also lowered his price target on the shares to $2 from $4.
08/09/19
MUFG
08/09/19
NO CHANGE
Target $3.5
MUFG
Neutral
Southwestern Energy price target lowered to $3.50 from $4.50 at MUFG
MUFG analyst Michael McAllister lowered his price target on Southwestern Energy to $3.50 and kept his Neutral rating after its Q2 earnings miss. The analyst notes that the "sharp" decline in natural gas prices should preserve the company's original 2019 plan for capacity as it forecasts a drop from 6 rigs to 2 by the end of Q3. With natural gas prices tipped to remain below $3 in the futures market until 2024, McAllister sees Southwestern Energy being several years away from benefiting from its investments.

TODAY'S FREE FLY STORIES

07:40
11/19/19
11/19
07:40
11/19/19
07:40
General news
Treasury Market Outlook: trading was pretty quiet overnight »

Treasury Market Outlook:…

FLT

FleetCor

$298.35

1.19 (0.40%)

07:39
11/19/19
11/19
07:39
11/19/19
07:39
Conference/Events
FleetCor management to meet with BTIG »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

PRIM

Primoris

$21.34

-0.31 (-1.43%)

07:38
11/19/19
11/19
07:38
11/19/19
07:38
Hot Stocks
Primoris announces industrial awards valued over $30M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. expects cash, cash equivalents to fund operations into 4Q21 »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ECL

Ecolab

$191.28

-0.45 (-0.23%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:37
11/19/19
11/19
07:37
11/19/19
07:37
Hot Stocks
Affimed N.V. appoints Cassandra Choe-Juliak as acting CMO »

Affimed announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Hot Stocks
Affimed N.V. plans preclinical studies for AFM28, AFM32 in 2020 »

Affimed selected two new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FB

Facebook

$197.45

2.38 (1.22%)

, BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

07:35
11/19/19
11/19
07:35
11/19/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

FB

Facebook

$197.45

2.38 (1.22%)

BMY

Bristol-Myers

$57.62

-0.99 (-1.69%)

LK

Luckin Coffee

$28.17

1.11 (4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

PTON

Peloton

$30.22

2.94 (10.78%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Recommendations
Peloton analyst commentary  »

JPMorgan reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MXL

MaxLinear

$19.84

-0.2 (-1.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Upgrade
MaxLinear rating change  »

MaxLinear upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$0.00

(0.00%)

07:34
11/19/19
11/19
07:34
11/19/19
07:34
Conference/Events
Esterline management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:33
11/19/19
11/19
07:33
11/19/19
07:33
Hot Stocks
Affimed N.V. to initiate Phase 1/2a study of AFM24 in 1Q20 »

In October 2019, Affimed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MBRX

Moleculin Biotech

$1.04

(0.00%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Hot Stocks
Moleculin Biotech reports preliminary data from clinical trial of WP1220 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGYI

Youngevity

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Recommendations
Youngevity analyst commentary  »

Youngevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$38.84

-1.72 (-4.24%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$58.35

0.1 (0.17%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Upgrade
Ventas rating change  »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFMD

Affimed N.V.

$2.43

-0.045 (-1.82%)

07:32
11/19/19
11/19
07:32
11/19/19
07:32
Earnings
Affimed N.V. reports Q3 EPS (EUR0.17) vs. (EUR0.19) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PGNY

Progyny

$24.89

1.095 (4.60%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Initiation
Progyny initiated  »

Progyny initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CINF

Cincinnati Financial

$107.85

0.84 (0.78%)

07:31
11/19/19
11/19
07:31
11/19/19
07:31
Conference/Events
Cincinnati Financial management to meet with Buckingham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TSM

TSMC

$53.41

0.12 (0.23%)

, RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

07:30
11/19/19
11/19
07:30
11/19/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSM

TSMC

$53.41

0.12 (0.23%)

RVLV

Revolve Group

$15.15

-0.315 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$145.61

-0.75 (-0.51%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$414.70

7.7 (1.89%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Conference/Events
Chemed management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

VRCA

Verrica Pharmaceuticals

$14.35

-0.35 (-2.38%)

07:29
11/19/19
11/19
07:29
11/19/19
07:29
Hot Stocks
Verrica Pharmaceuticals announces passing of board member Glenn Oclassen »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$103.80

2.31 (2.28%)

07:28
11/19/19
11/19
07:28
11/19/19
07:28
Recommendations
Fortinet analyst commentary  »

Fortinet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

AVGO

Broadcom

$310.95

-1.86 (-0.59%)

07:27
11/19/19
11/19
07:27
11/19/19
07:27
Upgrade
Broadcom rating change  »

Broadcom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.